Yazar "Arıcı, Serdar" için listeleme
-
The conversion ofRASstatus in metastatic colorectal cancer patients after first-line biological agent treatment
Arıcı, Serdar; Hamdard, Jamshid; Sakin, Abdullah; Şengiz Erhan, Selma; Atçı, Muhammed Mustafa; Cekin, Ruhper; Saka, Burcu; Köse, Emin; Saydam, Tuba; Geredeli, Çağlayan; Cihan, Şener; Bilici, Ahmet (Wiley, 2021)Aim The aim was to investigate theRASdiscordance between initial and recurrent metastasectomy specimens in metastatic colorectal cancer (mCRC) patients treated with chemotherapy (CT) plus biological agents in a first-line ... -
The predictive importance of body mass index on response to neoadjuvant chemotherapy in patients with breast cancer
Emirzeoğlu, Levent; Arıcı, Serdar; Şahin, Ahmet Bilgehan; Ocak, Birol; Ak, Naziye; Ay, Seval; Mammadov, Elkhan; Turna, Hande; Bilici, Ahmet (Karger, 2023)Purpose: The aim of the study was to investigate the effects of body mass index (BMI) on the response to neoadjuvant chemotherapy (NACT) in Turkish patients with local and locally advanced breast cancer. Methods: The ... -
Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer
Kutlu, Yasin; Çekin, Ruhper; Göktaş Aydın, Sabin; Shbair, Abdallah T. M.; Bilici, Ahmet; Arıcı, Serdar; Öven, Bala Başak; Açıkgöz, Özgür; Özcan, Erkan; Ölmez, Ömer Fatih; Çakır, Aslı; Şeker, Mesut (2024)Loss of human epidermal growth factor receptor 2 (HER2) expression can be seen in almost 25–30 % patients after HER2 receptor directed neoadjuvant treatment. These patients have unclear clinical outcomes in previous studies. ...